Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:HURA NASDAQ:ORKA NASDAQ:SIGA NASDAQ:ZYBT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeHURATuHURA Biosciences$2.65+3.9%$2.81$1.80▼$7.93$115.97M0.17262,583 shs167,260 shsORKAOruka Therapeutics$13.72-0.4%$12.07$5.49▼$31.13$511.44M-0.34233,703 shs45,292 shsSIGASiga Technologies$6.82-0.4%$6.33$4.95▼$12.83$486.86M0.94709,895 shs93,639 shsZYBTZhengye Biotechnology$5.55-2.5%$7.29$3.50▼$14.30$261.79MN/A346,543 shs6,483 shsThese 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceHURATuHURA Biosciences-2.67%+9.44%0.00%-37.50%+254,999,900.00%ORKAOruka Therapeutics-5.30%-6.33%+17.89%+30.15%+1,376,999,900.00%SIGASiga Technologies+3.63%-0.15%+11.93%+11.75%-26.58%ZYBTZhengye Biotechnology0.00%-3.07%-38.82%-36.85%+568,999,900.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationHURATuHURA Biosciences1.7956 of 5 stars3.70.00.00.03.00.00.0ORKAOruka Therapeutics2.7913 of 5 stars3.60.00.00.02.52.50.6SIGASiga Technologies1.9974 of 5 stars0.03.00.00.01.30.83.1ZYBTZhengye BiotechnologyN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceHURATuHURA Biosciences 3.40Buy$12.67377.99% UpsideORKAOruka Therapeutics 3.20Buy$40.38194.28% UpsideSIGASiga Technologies 0.00N/AN/AN/AZYBTZhengye Biotechnology 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest HURA, ZYBT, ORKA, and SIGA Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/21/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform$40.006/23/2025HURATuHURA BiosciencesBrookline Capital ManagementSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy5/22/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy5/22/2025ORKAOruka TherapeuticsBTIG ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy$44.005/16/2025HURATuHURA BiosciencesHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$12.00 ➝ $12.005/15/2025ORKAOruka TherapeuticsWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.00(Data available from 7/22/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookHURATuHURA BiosciencesN/AN/AN/AN/A$0.34 per shareN/AORKAOruka TherapeuticsN/AN/AN/AN/A$10.84 per shareN/ASIGASiga Technologies$138.72M3.51$0.86 per share7.90$3.02 per share2.26ZYBTZhengye Biotechnology$25.53M10.25$0.10 per share55.22$1.02 per share5.44Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateHURATuHURA Biosciences-$21.68MN/A0.00∞N/AN/A291.69%122.09%10/6/2025 (Estimated)ORKAOruka Therapeutics-$83.72M-$4.51N/AN/AN/AN/A-25.66%-23.39%7/30/2025 (Estimated)SIGASiga Technologies$59.21M$0.6710.175.46N/A40.30%25.21%22.05%7/30/2025 (Estimated)ZYBTZhengye Biotechnology$1.55MN/A0.00∞N/AN/AN/AN/AN/ALatest HURA, ZYBT, ORKA, and SIGA EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/7/2025Q1 2025ORKAOruka Therapeutics-$0.48N/AN/AN/AN/AN/A5/15/2025Q1 2025HURATuHURA Biosciences-$0.13-$0.15-$0.02-$0.15N/AN/A5/14/2025Q1 2025ORKAOruka Therapeutics-$0.57-$0.40+$0.17-$0.40N/AN/A5/8/2025Q1 2025SIGASiga TechnologiesN/A-$0.01N/A-$0.01N/A$7.04 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthHURATuHURA BiosciencesN/AN/AN/AN/AN/AORKAOruka TherapeuticsN/AN/AN/AN/AN/ASIGASiga TechnologiesN/AN/AN/AN/AN/AZYBTZhengye BiotechnologyN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioHURATuHURA BiosciencesN/A3.003.00ORKAOruka TherapeuticsN/A30.0330.03SIGASiga TechnologiesN/A8.406.28ZYBTZhengye Biotechnology0.011.310.88Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipHURATuHURA Biosciences0.62%ORKAOruka Therapeutics56.44%SIGASiga Technologies55.40%ZYBTZhengye BiotechnologyN/AInsider OwnershipCompanyInsider OwnershipHURATuHURA Biosciences0.20%ORKAOruka Therapeutics24.69%SIGASiga Technologies1.95%ZYBTZhengye BiotechnologyN/ACompare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableHURATuHURA BiosciencesN/A43.68 million43.59 millionN/AORKAOruka TherapeuticsN/A37.44 million28.20 millionN/ASIGASiga Technologies4071.44 million70.05 millionOptionableZYBTZhengye Biotechnology27847.17 millionN/AN/AHURA, ZYBT, ORKA, and SIGA HeadlinesRecent News About These CompaniesZYBT | Zhengye Biotechnology Holding Ltd. Company Profile & Executives ...July 17, 2025 | wsj.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial Results | ZYBT Stock NewsJuly 3, 2025 | gurufocus.comZhengye Biotechnology Holding Limited Announces Fiscal Year 2024 Financial ResultsJuly 3, 2025 | prnewswire.comZYBT | Zhengye Biotechnology Holding Ltd. Stock Overview (U.S.: Nasdaq) - Barron'sJuly 2, 2025 | barrons.comZhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) Lock-Up Period Will End on July 7thJune 30, 2025 | marketbeat.comZYBT - Zhengye Biotechnology Holding Ltd Chart - MorningstarJune 27, 2025 | morningstar.comMZhengye Biotechnology Holding LtdJune 21, 2025 | morningstar.comMZYBT Zhengye Biotechnology Holding LimitedMay 30, 2025 | seekingalpha.comZhengye Biotechnology faces NASDAQ compliance issueMay 24, 2025 | investing.comZhengye Biotechnology Holding Limited Receives NASDAQ Delinquency Letter for Non-Compliance with Listing RequirementsMay 23, 2025 | quiverquant.comQZhengye Biotechnology Holding Limited Receives NASDAQ Notice Related to Late Filing of Form 20-FMay 23, 2025 | globenewswire.comShould We Be Cautious About Zhengye Biotechnology Holding Limited's (NASDAQ:ZYBT) ROE Of 6.9%?April 7, 2025 | finance.yahoo.comZhengye Biotechnology Holding Ltd.April 3, 2025 | wsj.comZhengye Biotechnology Holding Limited (ZYBT)March 27, 2025 | finance.yahoo.comZhengye Biotechnology Holding Limited Announces Full Exercise of Underwriters' Over-Allotment OptionJanuary 14, 2025 | globenewswire.comZhengye Biotechnology Holding Limited Announces Closing of Initial Public OfferingJanuary 8, 2025 | globenewswire.comZhengye Biotechnology Holding Limited Announces Pricing of Initial Public OfferingJanuary 6, 2025 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeHURA, ZYBT, ORKA, and SIGA Company DescriptionsTuHURA Biosciences NASDAQ:HURA$2.65 +0.10 (+3.92%) As of 01:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.TuHURA Biosciences, Inc. (NASDAQ: HURA) is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. TuHURA is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda® (pembrolizumab) in first line treatment for advanced or metastatic Merkel Cell Carcinoma. In addition to its innate immune response agonist candidates, TuHURA is leveraging its Delta receptor technology to develop first-in-class bi-specific ADCs, and PDCs targeting Myeloid Derived Suppressor Cells to inhibit their immune suppressing effects on the tumor microenvironment to prevent T cell exhaustion and acquired resistance to checkpoint inhibitors and cellular therapies.Oruka Therapeutics NASDAQ:ORKA$13.72 -0.05 (-0.36%) As of 01:21 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.Siga Technologies NASDAQ:SIGA$6.82 -0.03 (-0.44%) As of 01:20 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.SIGA Technologies, Inc., a commercial-stage pharmaceutical company, focuses on the health security related markets in the United States. Its lead product is TPOXX, an oral formulation antiviral drug for the treatment of human smallpox disease caused by variola virus. The company was incorporated in 1995 and is headquartered in New York, New York.Zhengye Biotechnology NASDAQ:ZYBT$5.55 -0.14 (-2.46%) As of 01:02 PM EasternZhengye Biotechnology Holding Limited is a veterinary vaccine manufacturer which encompasses research, development, manufacturing and sales of veterinary vaccines, with a focus on livestock vaccine principally in China. Zhengye Biotechnology Holding Limited is based in Jilin, China. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Rigetti Soars 30% on Latest Quantum Leap: What It Means Long-Term Domino’s Delivers Another Discounted Entry for Income Investors 3 Reasons Palo Alto Networks Is Becoming a Wall Street Favorite Vertical Aerospace Stock Trades at Discount After VX4 Milestone GameStop: Clarity Brings Renewed Confusion for Meme Stock Analysts Are Backing Qualcomm: Is a Breakout Coming? TSLA Earnings Week: Can Tesla Break Through $350? D-Wave Rises 12% in 1 Day, Beating Rivals: What Caused the Spike? Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
